Novartis buys Takeda dry eye drug

Swiss drugmaker Novartis is buying Takeda Pharmaceutical’s dry eye drug Xiidra for an upfront payment of US$3.4bn to expand its portfolio of eye care medicines. The deal includes potential milestone…